Stress degradation studies on ezetimibe and development of a validated stability-indicating HPLC assay

被引:111
作者
Singh, S
Singh, B
Bahuguna, R
Wadhwa, L
Saxena, R
机构
[1] NIPER, Dept Pharmaceut Anal, Nagar 160062, Punjab, India
[2] Ind Swift Labs Ltd, Patiala, Punjab, India
关键词
ezetimibe; degradation; stress testing; stability-indicating; assay; validation;
D O I
10.1016/j.jpba.2006.01.030
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Ezetimibe was subjected to different ICH prescribed stress conditions. Degradation was found to occur in hydrolytic and to some extent in photolytic conditions, while the drug was stable to oxidative and thermal stress. The drug was particularly labile under neutral and alkaline hydrolytic conditions. A stability-indicating HPLC method was developed for analysis of the drug in the presence of the degradation products. It involved a C-8 column and a mobile phase composed of ammonium acetate buffer (0.02 M, pH adjusted to 7.0 with ammonium hydroxide) and acetonitrile, which was pushed through the column in a gradient mode. The detection was carried out at 250 nm. The method was validated for linearity, range, precision, accuracy, specificity, selectivity and intermediate precision. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:1037 / 1040
页数:4
相关论文
共 6 条
  • [1] [Anonymous], [No title captured]
  • [2] Development of validated stability-indicating assay methods - critical review
    Bakshi, M
    Singh, S
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) : 1011 - 1040
  • [3] A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe
    Ezzet, F
    Krishna, G
    Wexler, DB
    Statkevich, P
    Kosoglou, T
    Batra, VK
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (06) : 871 - 885
  • [4] ICH (Q1A R2), 2003, INT C HARM IFPMA GEN
  • [5] Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms
    Sistla, R
    Tata, VSSK
    Kashyap, YV
    Chandrasekar, D
    Diwan, PV
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 39 (3-4) : 517 - 522
  • [6] (2R*,3R*,6S*)-N,6-Bis(4-fluorophenyl)-2-(4-hydroxy-phenyl)-3,4,5,6-tetrahydro-2H-pyran-3-carboxamide
    Swamy, GYSK
    Ravikumar, K
    Wadhwa, LK
    Saxena, R
    Singh, S
    [J]. ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2005, 61 : O3608 - O3610